今天是:   返回主页   |   加入收藏   |   联系我们
引用本文:
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  下载PDF阅读器  关闭
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1905次   下载 1928 本文二维码信息
码上扫一扫!
分享到: 微信 更多
通补心宝胶囊治疗慢性充血性心力衰竭临床机制研究
黄传惠1, 樊瑞红2
1.天津中医药大学 300193;2.天津市中医药研究院附属医院 300120
摘要:
[目的]通过比较通补心宝胶囊和补益强心片治疗慢性充血性心力衰竭(CHF)临床疗效和对CHF患者血浆内皮素(ET)、一氧化氮(N0)及脑钠肽(BNP)的影响观察。[方法]选取120例心肾阳虚、血瘀湿阻型慢性充血性心力衰竭患者,采用随机数字表法,随机将其分为治疗组和对照组,两组均口服常规西药,治疗组加服通补心宝胶囊,对照组加服补益强心片,2个月为1个疗程。观察两组患者治疗前后中医证候、生活质量、心功能、心脏彩色多普勒超声心动图、血浆ET、NO、BNP指标检测。[结果]与对照组比较,治疗组心衰症状、生活质量及心功能明显提高(P<0.05),射血分数(EF)、心室舒缩末期内径(LVESD)均有明显改善(P<0.05),治疗组NO、ET及BNP水平明显降低(P<0.05)。[结论]通补心宝胶囊在改善慢性充血性心力衰竭症状、生活质量的同时能明显抑制CHF患者血浆ET、NO水平升高,降低BNP水平,且能明显改善和调整CHF血流动力学。
关键词:  通补心宝胶囊  充血性心力衰竭  临床与机制  研究
DOI:10.11656/j.issn.1673-9043.2012.02.07
分类号:
基金项目:
Clinic and mechanism study of Tongbu Xinbao capsule on congestive heart failure
HUANG Chuan-hui1, FAN Rui-hong2
1.Tianjin University of TCM, Tianjin 300193, China;2.Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China
Abstract:
[Objective] To compare the effect of Tongbu Xinbao capsules (TBXBCs) and Buyi Qiangxin tablets (BYQXTs) on chronic congestive heart failure (CHF) and observe the level of plasma endothelin (ET), nitric oxide (NO) and brain natriuretic peptide (BNP) in CHF patients.[Methods] The 120 CHF patients with heart and kidney Yang deficiency and internal water and dampness retention were selected and using a randomized single blind method they were divided into treatment group and control group. The patients in both groups were given routine Western medicine, but TBXBCs were added in treatment group and BYQXTs in control group. Two months was one course. TCM syndrome before and after treatment, quality of life, heart function, heart color Doppler ultrasonic echocardiography, plasma ET, NO, BNP of two groups were observed.[Results] Compared with control group, the heart failure symptoms, quality of life and heart function were significantly improved in treatment group (P<0.05). The ejection fraction (EF) and the left ventricular end-systolic dimension (LVESD) were improved significantly (P<0.05); NO, ET and BNP were significantly decreased in treatment group (P<0.05).[Conclusion] TBXBCs can improve symptoms and quality of life in CHF patients and can significantly inhibit the increasing of plasma ET, NO levels, decrease the level of BNP at the same time. It can also significantly improve and adjust the CHF hemodynamics.
Key words:  Tongbu Xinbao capsule  CHF  clinic and mechanism  study
关注公众号二维码